Injectable SN-38-embedded polymeric microparticles promote antitumor efficacy against malignant glioma in an animal model

Yuan Yun Tseng, Tao Chieh Yang, Shu Mei Chen, Shun Tai Yang, Ya Ling Tang, Shih Jung Liu

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Malignant glioma (MG) is extremely aggressive and highly resistant to chemotherapeutic agents. Using electrospraying, the potent chemotherapeutic agent 7-ethyl-10-hydroxycamptothecia (SN-38) was embedded into 50:50 biodegradable poly[(D,L)-lactide-co-glycolide] (PLGA) microparticles (SMPs). The SMPs were stereotactically injected into the brain parenchyma of healthy rats and intratumorally injected into F98 glioma-bearing rats for estimating the pharmacodynamics and therapeutic efficacy. SN-38 was rapidly released after injection and its local (brain tissue) concentration remained much higher than that in the blood for more than 8 weeks. Glioma-bearing rats were divided into three groups—group A (n = 13; stereotactically injected pure PLGA microparticles), group B (n = 12; stereotactically injected Gliadel wafer and oral temozolomide), and group C (n = 13; stereotactic and intratumoral introduction of SMPs). The SMPs exhibited significant therapeutic efficacy, with prolonged survival, retarded tumor growth, and attenuated malignancy. The experimental results demonstrated that SMPs provide an effective and potential strategy for the treatment of MG.

Original languageEnglish
Article number479
JournalPharmaceutics
Volume12
Issue number5
DOIs
Publication statusPublished - May 2020

Keywords

  • 7-ethyl-10-hydroxycamptothecia (SN-38)
  • Intratumoral drug delivery
  • Irinotecan (CPT-11)
  • Malignant glioma (MG)
  • Poly(lactide-co-glycolide) (PLGA)

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Injectable SN-38-embedded polymeric microparticles promote antitumor efficacy against malignant glioma in an animal model'. Together they form a unique fingerprint.

Cite this